T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
- Conditions
- LeukemiaMultiple MyelomaLymphomaPlasma Cell NeoplasmMyelodysplastic Syndromes
- Interventions
- Biological: umbilical cord blood transplantationRadiation: Total body irradiationBiological: Treg infusion
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 41
- Registration Number
- NCT00602693
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
- Conditions
- Epidermolysis Bullosa
- Interventions
- Procedure: hematopoietic bone marrow transplantation
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00478244
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
- Conditions
- Dyskeratosis CongenitaAplastic Anemia
- Interventions
- Procedure: Total Body IrradiationProcedure: Stem Cell TransplantationDrug: antithymocyte globulin
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 36
- Registration Number
- NCT00455312
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- Conditions
- Childhood Germ Cell TumorOvarian CancerTeratoma
- Interventions
- Procedure: autologous hematopoietic stem cell transplantationBiological: filgrastim
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00428194
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 38
- Registration Number
- NCT00400803
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Hubert H. Humphrey Cancer Center, Minneapolis, Minnesota, United States
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: anti-thymocyte globulinProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 24
- Registration Number
- NCT00392782
- Locations
- 🇺🇸
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
HSCT for High Risk Inherited Inborn Errors
- Conditions
- Globoid Cell LeukodystrophyI-Cell DiseaseAdrenoleukodystrophyWolman DiseaseSanfilippo SyndromeGM1 GangliosidosisMetachromatic LeukodystrophyTay Sachs DiseaseSandhoffs Disease
- Interventions
- Procedure: Total body IrradiationBiological: Hematopoietic Stem Cell TransplantationDrug: mycophenylate mofetilDevice: Cyclosporine A
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 38
- Registration Number
- NCT00383448
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
- Conditions
- ThromboembolismVaginal CancerFallopian Tube CancerSarcomaOvarian CancerEndometrial CancerVulvar CancerCervical Cancer
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT00381888
- Locations
- 🇺🇸
Crozer-Chester Medical Center, Upland, Pennsylvania, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 13
- Registration Number
- NCT00379197
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States